TLR3 and astrocytoma (excluding glioblastoma): IMA950 in combination with poly-ICLC (a synthetic TLR3 ligand) exhibited safety, tolerance, and immunogenicity in malignant astrocytoma patients (16 glioblastomas and 3 grade III astrocytoma) in phase 1/2 clinical trials (intradermally, intramuscularly, or subcutaneously).